Tempest Therapeutics, Inc. TPST NASDAQ

Tempest Therapeutics, Inc. (TPST) reported total assets of $16.93M and total liabilities of $10.26M for fiscal year 2025, resulting in total equity of $6.67M.

The company held $7.71M in cash and short-term investments. Total debt stood at $8.14M, with net debt of $434K. The Debt-to-Equity (D/E) ratio was 1.22 (moderate).

Current ratio is 2.5, indicating strong short-term liquidity. Interest coverage is -128.4x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (28/100) — Total assets $16.93M and equity $6.67M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 1.22 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 51/100 with 2/7 criteria passed.

RVMD

Revolution Medicines, Inc.

$147.01

+7.86%

OLMA

Olema Pharmaceuticals, Inc.

$16.30

+2.32%

GLUE

Monte Rosa Therapeutics, Inc.

$17.50

-0.28%

SANA

Sana Biotechnology, Inc.

$3.48

+8.41%

LIFE

aTyr Pharma, Inc.

$14.69

+2.23%

CGEM

Cullinan Oncology, Inc.

$14.35

+0.70%

IKNA

Ikena Oncology, Inc.

$17.16

+1,152.55%

LYEL

Lyell Immunopharma, Inc.

$23.37

-5.77%